Invivo Therapeutics HoldingsNVIVQ
13F holders, Q1 2024 (March 31)4holders
$0.22avg. 13F price*
At the end of Q1 2024, 4 institutions reported holding Invivo Therapeutics Holdings (NVIVQ) in their 13F filings. The largest holders were Goldman Sachs Group Inc. ($5K), Vima LLC ($2) and Barclays PLC ($0).
- Company
- Invivo Therapeutics Holdings
- CUSIP
- 46186M605
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $5K |
| Exits | 13 | $68K |
Ownership 4 holders
| Goldman Sachs Group Inc. | 0.00% | New | 23,741 | $5K |
| Vima LLC | 0.00% | No change | 2 | $2 |
| Barclays PLC | 0.00% | New | 2 | $0 |
| Sugarloaf Wealth Management, LLC | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is NVIVQ's weight in each manager's 13F, not the share of Invivo Therapeutics Holdings the manager owns.